23 studies found for:    Tysabri | Open Studies
Show Display Options
Rank Status Study
1 Not yet recruiting Phase II Trial of Natalizumab (Tysabri®) Plus Prednisone for Initial Therapy of Acute Graft Versus Host Disease (aGVHD) of the Gastrointestinal Tract
Condition: Graft Versus Host Disease
Interventions: Drug: Natalizumab;   Drug: Methylprednisolone
2 Recruiting Tysabri Effects on Cognition and Neurodegeneration in Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Drug: Tysabri
3 Recruiting TOP: IMA-06-02 Tysabri Observational Program
Condition: Relapsing Remitting Multiple Sclerosis
Intervention: Drug: Natalizumab
4 Not yet recruiting Immunogenicity and Safety Study of Natalizumab (BG00002) Administered to Participants With Relapsing Multiple Sclerosis
Condition: Relapsing Multiple Sclerosis
Intervention: Drug: BG00002 (natalizumab)
5 Not yet recruiting Real-world Outcomes on Tecfidera® (BG00012, Dimethyl Fumarate) Post-Tysabri® (BG00002, Natalizumab)
Condition: Relapsing-Remitting Multiple Sclerosis
Interventions: Biological: BG00002 (Natalizumab);   Drug: BG00012 (dimethyl fumarate)
6 Recruiting The Effect of Natalizumab (Tysabri) on Sexual Dysfunction in Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Drug: Tysabri ® (Natalizumab)
7 Recruiting CD INFORM: Investigating Natalizumab Through Further Observational Research and Monitoring
Condition: Crohn's Disease
Intervention: Drug: Natalizumab
8 Recruiting PK and PD Study of Natalizumab in Pediatric Subjects With RRMS
Condition: Relapsing-Remitting Multiple Sclerosis
Intervention: Biological: Natalizumab
9 Not yet recruiting Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease
Condition: Acute Graft Versus Host Disease
Interventions: Drug: natalizumab;   Drug: steroids
10 Recruiting Ireland TYSABRI® (Natalizumab) Observational Program (iTOP)
Conditions: Multiple Sclerosis, Relapsing-Remitting;   Relapsing Remitting Multiple Sclerosis
Intervention:
11 Not yet recruiting Alternative Treatment Paradigm for Natalizumab Trial
Condition: Multiple Sclerosis (MS)
Intervention: Drug: methylprednisolone
12 Recruiting Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention:
13 Unknown  Neurocognitive Changes in Patients With Remitting Relapsing Multiple Sclerosis Treated With Natalizumab
Conditions: Multiple Sclerosis;   Cognitive Impairment
Intervention:
14 Recruiting Difference in Efficacy of Natalizumab Versus Fingolimod for the Treatment of Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention:
15 Unknown  Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Condition: Relapsing-remitting Multiple Sclerosis
Intervention:
16 Recruiting Safety and Effectiveness of Switching Relapsing MS Patients Treated With Natalizumab at Risk for PML to Teriflunomide
Condition: Multiple Sclerosis
Intervention: Drug: teriflunomide
17 Recruiting Impact Study of 2 Therapeutic Strategy for Aggressive Remitting Multiple Sclerosis
Condition: Multiple Sclerosis
Interventions: Other: mitoxantrone - immunomodulator;   Other: natalizumab
18 Recruiting Effect of Natalizumab on Infarct Volume in Acute Ischemic Stroke
Condition: Acute Ischemic Stroke
Interventions: Biological: BG00002 (Natalizumab);   Drug: Placebo
19 Recruiting Genetic Evaluation of Natalizumab-Treated Patients With Progressive Multifocal Leukoencephalopathy
Condition: Progressive Multifocal Leukoencephalopathy
Intervention:
20 Unknown  A Study of MSDx Complex 1 as a Marker for Therapy Response in Multiple Sclerosis
Condition: Relapsing Remitting Multiple Sclerosis
Intervention: Other: MSDX Complex-1 Biomarker test

Previous Page Studies Shown (1-20) Next Page (21-23) Show next page of results
Indicates status has not been verified in more than two years